Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

ne million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... solutions, today announced its GHS Label Guide . To align chemical container ... (GHS), this guide includes explanations of label components, an example of an accurate ...
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for ... that are able to enter fat cells, inhibiting the formation of new fat. ...
(Date:7/28/2015)... , July 29, 2015 ... acquiring, rapidly developing and commercialising innovative ... health   Highly experienced management team; blue ...   Mereo BioPharma Group Ltd ("Mereo"), ... raised $119m ( c. £76.5m), gross, from blue chip ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... Shachar Tauber, Stephen Slade, R. Wayne Bowman, William ... Stoneciper, Brock Magruder, and Richard Braunstein, attended the ... the Allegretto Wave excimer laser system used for ... eye surgeons and refractive experts are listed in ...
... VIRGINIA BEACH, Va., Oct. 30, 2008 AMERIGROUP,Corporation (NYSE: ... Best Places to Work,In Healthcare -- and the best ... by Modern Healthcare magazine., The survey, which was ... open to all American hospitals, medical practices and other,companies ...
... Oct. 30 Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ... development of drugs for the treatment of human ... results,for the third quarter and nine months ended ... cash equivalents and marketable,securities totaled approximately $60.1 million., ...
Cached Biology Technology:Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 2Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 3Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 4Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 5Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 6Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 7Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 8AMERIGROUP Corporation Named One of Best Places to Work in Healthcare 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 3Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 4Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 5Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 6Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 7
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... cells) are involved in activating and directing other immune ... the over-aggressive responses of the T cell population. , ... anti-tumor Teff cells in order to better shape the ... from Memorial Sloan-Kettering Cancer Center, New York, demonstrated that ...
... function test scores by more than 15 percent in less ... second issue for July 2006 of the American Journal of ... Society. , Neil C. Thomson, M.D., of the Departments of ... seven associates studied 11 asthmatics who continued to smoke and ...
... only serves as a physical barrier against infection but skin ... microbes by producing antimicrobial polypeptides (AMPs). , As overt infection ... that AMPs must not only help fight infection, but play ... place. In a study appearing online on June 15 in ...
Cached Biology News:Quitting smoking improves lung function considerably 2
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
Weinreb Linker...
Biology Products: